Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma

Clinical trial NCT07022223 · RECRUITING

Trial details

NCT number: NCT07022223
Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Marginal Zone Lymphoma(MZL)

Start date: 2025-03-11
Primary completion: 2027-09-11
Enrollment: 51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.